All In Biotech

Drug Trial Radar · NCT06533553

A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

An Open-label Phase II Study to Assess the Pharmacodynamic (PD) Effects of Dexpramipexole in Participants With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 9, 2024

Primary completion

Oct 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Areteia TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Dexpramipexole DihydrochlorideDrug

    Administration of dexpramipexole tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric mean change in the blood AEC from baseline to Week 16Time frame: Baseline, Week 16

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site US-10001-017

    Conway, Arkansas

  • Research Site US-10001-008

    Newport Beach, California

  • Research Site US-10001-022

    Northridge, California

  • Research Site US-10001-016

    Westminster, California

  • Research Site US-10001-030

    Orlando, Florida

  • Research Site 10001-032

    Champaign, Illinois

  • Research Site US-10001-021

    Hammond, Indiana

  • Research Site US-10001-033

    Des Moines, Iowa

  • Research Site US-10001-020

    Baltimore, Maryland

  • Research Site US-10001-024

    Farmington Hills, Michigan

  • Research Site US-10001-005

    Saint Charles, Missouri

  • Research Site US-10001-001

    St Louis, Missouri

  • Research US-10001-010

    Charlotte, North Carolina

  • Research Site US-10001-025

    Charlotte, North Carolina

  • Research Site US-10001-007

    Gastonia, North Carolina

  • Research Site US-10001-004

    Columbus, Ohio

  • Research Site US-10001-002

    DuBois, Pennsylvania

  • Research Site US-10001-013

    Philadelphia, Pennsylvania

  • Research Site US-10001-023

    East Providence, Rhode Island

  • Research Site US-10001-012

    Rock Hill, South Carolina

  • Research Site US-10001-009

    Corsicana, Texas

  • Research Site US-10001-038

    Houston, Texas

  • Research Site 10001-026

    McKinney, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.